Saturday, November 21, 2009 
|
|
|
| subscribe | manage account |
San Diego’s Top Influentials highlights the Who’s Who in San Diego business, profiling the top newsmakers of 2008. This year we focus on the leaders in Biotech, Tech & Defense; Construction; Finance; Law and Business & Consumer Services; and Real Estate.
Since 1886, The Daily Transcript has seen and reported on many significant changes to San Diego’s economic landscape, many of which stem from the remarkable ideas and contributions of individuals. We pay tribute to these prominent newsmakers — San Diego’s movers and shakers — with a special salute to the Top Influentials.
Since 1886, The Daily Transcript has seen and reported on many significant changes to San Diego’s economic landscape, many of which stem from the remarkable ideas and numerous contributions of single individuals. These individuals have impacted our lives, our communities, our economy. Now, we pay tribute to these prominent newsmakers – San Diego’s movers and shakers – with a special salute to the 120 Top Influentials.
As The Daily Transcript celebrates its 120th year in print, our editorial board -- with help from the San Diego Historical Society -- reflects back on our region’s rich history. In this feature, we pay tribute to some of the pioneers who played an integral part in laying the foundation for San Diego’s future growth. Read more about the contributions these individuals have made as the Transcript takes a brief look back through time.
In celebration of The Daily Transcript's 120th Anniversary, we pay tribute to the prominent business leaders -- past and present -- who have impacted the region. The Daily Transcript thanks its sponsors for participating in this anniversary publication.
11388 Sorrento Valley Rd.
San Diego, CA 92121
Avanir Pharmaceuticals recently received an approvable letter from the FDA regarding its lead product candidate for the treatment of involuntary emotional expression disorder, Zenvia. While that doesn't mean the drug is approved for marketing in the United States at this time, Avanir President and CEO Eric Brandt is optimistic about its outlook.
If approved, Avanir would have the first drug of its kind on the market, with an estimated patient population of 1 million people. It also would be the first time Avanir would promote and sell a drug it developed, rather than licensing the drug out to marketing partners.
Yet Zenvia is just one of several moving parts in a changing company. Avanir is consolidating its San Diego offices and laboratory space into one building, with plans to keep research and development here, but move office support and commercial activities to a new headquarters facility in Orange County.